The firm then sold three of Catalent's plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion ... rely on manufacturers in China and India to look for western ...

Novo Nordisk A/S is prepared for potential ... tariffs on key trading partners Canada, Mexico and China, which has left some manufacturing companies scrambling to react. The US is a key market ...

The new plant will be one of the largest manufacturing investments in Novo Nordisk’s history and will add 1.4 million sq ft of production space for aseptic manufacturing and finished production ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

The firm then sold three of Catalent's plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion as part of ... drugmakers that currently rely on manufacturers in China ...